{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"To determine tumor EGFR degradation, as well as other markers of down-stream EGFR inhibition, observed in tumor biopsies taken shortly after the administration of cetuximab following TPF, compared with pre-treatment biopsies.","groups":[{"description":"Patients will undergo induction chemotherapy with (TPF): Docetaxel (Taxotere) 75 mg/m2 and cisplatin 100 mg/m2 on day 1, and 5-FU 750 mg/m2 days 1-4.\n\nOn day 20 patients will receive a single dose of cetuximab (C-225) 400 mg/m2.\n\nDepending upon disease response, patients will undergo salvage laryngectomy followed by radiation therapy and chemotherapy.","id":"OG000","title":"Chemotherapy/Radiation/Surgery"}],"populationDescription":"The study was discontinued prematurely due to an early stopping rule. No participants were assessed because an insufficient number of patients were recruited.","reportingStatus":"POSTED","timeFrame":"Day 23","title":"The Difference, From Baseline, in EGFR, for Tumor Biopsies Taken After the Administration of Cetuximab Following TPF.","type":"SECONDARY"}